Company: FTII
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001641172-25-025250
Chunk: 94

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 2
Chunk 94
---
 are currently required annually. The ASU does
not change how a public entity identifies its operating segments, aggregate them, or applies the quantitative threshold to determine
its reportable segments. The new disclosure requirements are also applicable to entities that account and report as a single operating
segment entity. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years
beginning after December 15, 2024. The Company adopted the guidance for the annual reporting period ended December 31, 2024. There was
no impact on the Company’s unaudited condensed financial statements.

Management
does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material
effect on our unaudited condensed financial statements.

11

Subsequent
Events

Extension
of Business Combination Period

On
July 18, 2025, the Company caused to be deposited $38,994 into the Company’s Trust account, allowing the Company to extend the
period of time it has to consummate its initial Business Combination from July 18, 2025 to August 18, 2025. 

Amended
and Restated Merger Agreement

On
August 6, 2025, the Company, entered into an Amended and Restated Agreement and Plan of Merger (the “Amended Merger Agreement”),
by and among the Company, Longevity Biomedical Holdings Corp., a Delaware corporation (“PubCo”), LBH Merger Sub, Inc., a
Delaware corporation and direct, wholly-owned subsidiary of the Company (“Merger Sub”), Longevity and Andrew Leo, solely
in the capacity as sellers representative. Capitalized terms herein, unless otherwise defined, shall have the meanings ascribed to them
in the Amended Merger Agreement.

The
Amended Merger Agreement provides that the parties thereto will enter into a business combination transaction (the “Business Combination”
and together with the other transactions contemplated by the Amended Merger Agreement, the “Transactions”), pursuant to which,
among other things, (i) Longevity will consummate Target Acquisitions (as defined below) upon the terms and subject to conditions set
forth therein and pursuant to the Target Acquisition Agreements (as defined therein), and (ii) immediately following the consummation
of the Target Acquisitions, the Company will merge with and into PubCo (the “Reorganization Merger